Zevra Therapeutics
ZVRA
51 hedge funds and large institutions have $22M invested in Zevra Therapeutics in 2021 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
115,661% more capital invested
Capital invested by funds: $19K → $22M (+$22M)
2,450% more funds holding
Funds holding: 2 → 51 (+49)
111% more call options, than puts
Call options by funds: $19.3M | Put options by funds: $9.14M
8.26% more ownership
Funds ownership: 0% → 8.26% (+8.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.14M |
| 2 |
Millennium Management
New York
|
+$1.86M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.72M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.55M |
| 5 |
Jane Street
New York
|
+$1.39M |
Top Sellers
ZVRA Hedge Fund Activity: Q1 2021 in Review
51 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2021, worth a combined $22M — up 115,661% from $19K a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ZVRA positions and 0 closed out — a net gain of 49 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $7.14M.
- 51 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2021, up from 2 in Q4 2020.
- Funds reported $22M of Zevra Therapeutics stock for Q1 2021, up 115,661% quarter-over-quarter.
- 49 funds opened new Zevra Therapeutics positions in Q1 2021 and 0 closed out, a net change of +49 holders.
- The largest Zevra Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $7.14M added.
Based on aggregated 13F filings for Q1 2021.